Skip to main content
. 2013 Apr 15;123(5):2119–2130. doi: 10.1172/JCI65425

Figure 3. Therapeutic effectiveness of ATP11B siRNA plus cisplatin in ovarian cancer models.

Figure 3

(A) Tumor growth in the A2780-CP20, SKOV3ip1, RMG2, and IGROV-CP20 ovarian cancer models. Each bar represents mean tumor weight + SEM (n = 10). Significantly decreased tumor growth was observed only in mice treated with ATP11B siRNA plus cisplatin. *P < 0.05 (B) Silencing ATP11B reduced tumor proliferation and increased tumor cell apoptosis in ovarian cancer tumors. Tissue sections from A2780-CP20 tumors were immunostained for the detection of proliferating cell nuclear antigen (PCNA) and TUNEL-positive cells to assess tumor proliferation and apoptosis, respectively. Tumor tissues from mice treated with ATP11B siRNA and those treated with ATP11B siRNA plus cisplatin showed significantly lower (*P < 0.001) proliferation and significantly higher (**P < 0.05) apoptotic rates compared with their corresponding controls. Percentages of proliferating and apoptotic cells were calculated in 5 fields for each tissue sample (n = 5). Data represent the mean ± SEM. Original magnification, ×200.